Lung and liver malignant tumors are prone to metastasize to each other On July 29, Mr. Mo, who always thought he was in good health, was dumbfounded when he received the report card of his unit physical examination, “There are shadows in the lungs and liver, and it is recommended to review as soon as possible.” Subsequently, Mr. Mo had a PET/CT, which confirmed that he had a 5cm diameter mass in his upper left lung and a 3cm diameter mass in the left lobe of his liver. Mr. Mo said that instead of waiting for death, he should face it positively. Why did Mr. Mo have no symptoms at all even though the tumor had developed to an advanced stage? Both lung cancer and liver cancer are highly insidious malignant tumors. 70% of lung cancers are found to have lymphatic metastases or organ metastases. 80% of liver cancers are found only in the middle and late stages. ”The lung and liver are the most important organs of the human circulatory system and digestive system, respectively, with rich blood flow, and once malignant tumors appear, they often metastasize to each other.” Wang Zheng said that the cancer cells in Mr. Mo’s lung formed metastases in his liver through blood flow. Fortunately, he presented with a single metastasis in a single organ, and had a chance for surgery despite being at an advanced stage. Joint minimally invasive surgery According to the past surgical plan, lung cancer resection is usually performed first, and then liver metastases are removed after the patient recuperates for one month. Could there be a better option? Carrying out minimally invasive surgery could solve Mr. Mo’s problem in the shortest possible time and also avoid the risk of the patient having to bear general anesthesia twice. Mr. Mo was informed of the plan and readily agreed. At 2 p.m., Wang Zheng first performed a total thoracoscopic left upper lung lobectomy on the patient, and close to three hours later, Liu Jialin started to remove the patient’s left half of the liver using laparoscopy. Since the mass grew in the second hepatic hilar position, which was very close to the large blood vessels, it was necessary to carefully dissect the first and second hepatic hilum and the arterioles and portal veins of the left liver, and then separate the liver tissues one by one with an ultrasonic knife. The surgery plus anesthesia took up to 10 hours, and Mr. Mo had almost no bleeding during the operation. After the surgery, Mr. Mo recovered very well and gradually resumed eating and getting out of bed. Three weeks after the operation, Mr. Mo’s treatment will be taken over by Zhang Yanfang, deputy director of the interventional department. Zhang Yanfang said that a hepatic artery catheter chemoembolization treatment plan has been developed for Mr. Mo. In the patient’s fully awake state, the highly concentrated chemotherapy drug is injected directly into the hepatocellular carcinoma vessels through a small needle-eye like hole under the image surveillance of a digital subtractor, so that the local area receives hundreds of times higher concentration of chemotherapy drugs than intravenous chemotherapy to produce the maximum anti-cancer effect. Zhang Yanfang said the interventional treatment that has emerged in recent years can effectively deal with cancer metastasis, recurrence and other inoperable conditions through three means, such as chemoembolization, ablation and particles, while having the same therapeutic effect as open surgery for small tumors in early stages. “Ninety percent of the patients in our department are liver cancer or liver metastatic cancer patients, and the use of interventional therapy can extend the survival of 80 percent of advanced patients from less than six months to one year, and 50 percent to two years, and even longer in some cases.”